Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma
NCT04833582Phase 1Completed
- Sponsor
- Zentalis Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of azenosertib in osteosarcoma (OS), sponsored by Zentalis Pharmaceuticals. Primary endpoints: Dose-Limiting Toxicities at 21 days and Event-Free Survival at 18 weeks. Started Aug 2021; status: completed.
02
Drugs
azenosertib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT04833582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04833582.